CRVO CervoMed Inc.
Company Analysis
Latest News
🟢 CervoMed is trading 5.7% up in pre-market amid positive initial Phase 2a biomarker data
CervoMed is trading 5.7% up in pre-market at $2.42, with positive initial Phase 2a biomarker data as context. - October 20 close: $2.29; no October 21 company...
CervoMed Retains Wainwright Buy Rating After Positive Phase 2a Data
On October 19, 2026, H.C. Wainwright reiterated its Buy rating and $25.00 price target for CervoMed Inc. The reaffirmation followed the company’s presentation...
🟢 CervoMed is trading 7.6% up in pre-market with no fresh catalyst identified
CervoMed is trading at $2.41, up 7.59%, in pre-market on October 19, with no fresh company-specific catalyst identified. - The October 16 close was $2.24. -...
🔴 CervoMed is trading 5% down; no company-specific cause identified
CervoMed is trading 5.29% down at $2.15, in a decline consistent with broader market pressure; no company-specific cause has been identified. -...
🟢 CervoMed is trading 5.7% up
CervoMed is trading 5.73% higher at $2.40 on October 14, 2026, with no company-specific announcement explaining the move identified in available coverage. -...
🔴 CervoMed is trading 10.9% down with no clear company-specific catalyst
CervoMed is trading at $2.24, down 10.88% on October 13; no clear company-specific explanation was found. - The October 12 update reported an early...
🔴 CervoMed is trading 5.6% down today with sector weakness a possible factor
CervoMed is trading at $2.37, down 5.58%, with healthcare-sector weakness a possible contributor that does not fully explain the decline. - Healthcare stocks...
CervoMed Reports Positive Initial Phase 2a Data for Neflamapimod in nfvPPA Trial
CervoMed Inc. announced positive initial data from the first 12 weeks of its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive...
🔴 CervoMed is trading 14% down — no confirmed catalyst
CervoMed is trading at $2.78, a -13.67% change, with no confirmed explanation for the decline. - As of October 12, 2026, no clearly confirmed company...
🔴 CervoMed is trading 13% down in pre-market with no clear catalyst identified
CervoMed is trading at $2.80, with a -13.04% change; no clearly linked new company announcement was identified to explain the decline. - CervoMed was...
🔴 CervoMed is trading 5% down today amid broad market weakness
CervoMed is trading at $3.17, down 5.24%, as broader risk-off sentiment provides the clearest available context for the decline. - No new company-specific...
🟢 CervoMed is trading 5% up in pre-market with no identified company catalyst
CervoMed is trading at $3.49, up 5.44% in pre-market versus its October 5 close of $3.31; no new company announcement explaining the move was identified. -...
🟢 CervoMed is trading 5% up
CervoMed is trading at $3.17, up +5.13%, after recent development updates, although no specific catalyst was identified for the rise. - On September 28,...
🟢 CervoMed is trading 5.4% up today after FDA removes neflamapimod exposure limit
CervoMed is trading 5.4% higher at $2.82 as of 10:47 a.m. ET on September 29, with its September 28 neflamapimod update the clearest potential catalyst. - The...
CervoMed Announces New Neflamapimod Formulation and Secures FDA Removal of Exposure Limit
CervoMed Inc. announced significant pharmacokinetic, regulatory, and manufacturing updates for its lead drug candidate, neflamapimod. The company has developed...
🟢 CervoMed is trading 5% up today amid a neflamapimod dosing update
CervoMed is trading at $2.67, up 5.12%, amid a neflamapimod dosing update that may be a company-specific catalyst; the release did not explicitly link the move...
🟢 CervoMed is trading 7% up in pre-market with no clear company-specific catalyst
CervoMed is trading at $2.72, up 7.09% in pre-market; no clear company-specific announcement explains the gain. - September 10 company news covered planned...
🟢 CervoMed is trading 5% up today amid broader market strength
CervoMed is trading at $2.53, up 5.18%, during the September 22, 2026 session as broader market strength lifts the Nasdaq Composite 0.51%, supported by easing...
🟢 CervoMed is trading 5% up today amid a broad market rally
CervoMed is trading up 5.33% now at $2.57, broadly moving with September 17, 2026’s risk-on market recovery. - The S&P 500, Nasdaq Composite, and Dow Jones...
🟢 CervoMed is trading 5% up today on broad market strength
CervoMed is trading 5.24% up at $2.61, supported primarily by broad market strength. - The S&P 500, Nasdaq Composite, and Dow Jones are all up more than 1% on...